is tirzepatide a lifelong drug Weight Loss Program Tirzepatide is a modern injectable

For non-diabetic obesity, the cleanest comparison is between two separate trials: STEP 1 (semaglutide 2.4 mg, Wilding et al., NEJM 2021): 14.9% body weight loss at 68 weeks SURMOUNT-1 (tirzepatide 15 mg, Jastreboff et al., NEJM 2022): 20.9% body weight loss at 72 weeks A roughly 6 percentage point gap in average weight loss favors tirzepatide

We determine your eligibility during a comprehensive initial consultation

Approximately three-quarters of patients initiating oral Wegovy had not previously received a GLP-1 injection, according to NorstellaLinQ data When available quickly, claims and EMR data do what claims data alone cannot

Int J Mol Sci 24:10449